Zdrowie i gospodarka · 30/09/2015

FDA Requests Notification from Industry Associations on Biosimilar User Fee Act Reauthorization

The FDA is seeking notification from industry associations representing drug companies involved in biosimilar development or manufacture to participate in stakeholder meetings supporting the reauthorization of the Biosimilar User Fee Act of 2012, which expires at the end of September 2017.